Ni Hms 509207

NIH Public Access
Author Manuscript
Schizophr Res. Author manuscript; available in PMC 2014 October 14.
Published in final edited form as:
NIH-PA Author Manuscript
Schizophr Res. 2013 October ; 150(1): 42–50. doi:10.1016/j.schres.2013.07.009.
The global cognitive impairment in schizophrenia: Consistent

over decades and around the world
Jonathan Schaefer, B.A.a, Evan Giangrandea, Daniel R. Weinberger, M.D.a,b, and Dwight
Dickinson, Ph.D, J.Da
aGenes, Cognition and Psychosis Program and Clinical Brain Disorders Branch, IRP, NIMH, NIH,
10 Center Drive, MSC 1379, Bethesda, Maryland 20892 USA
bLieberinstitute for Brain Development, Johns Hopkins University Medical Center 855 North
Wolfe Street, Baltimore, Maryland 21205 USA
Abstract
Objective—Schizophrenia results in cognitive impairments as well as positive, negative, and

disorganized symptomatology. The present study examines the extent to which these cognitive
deficits are generalized across domains, potential moderator variables, and whether the pattern of
cognitive findings reported in schizophrenia has remained consistent over time and across cultural
and geographic variation.
Method—Relevant publications from 2006 to 2011 were identified through keyword searches in
Pubmed and an examination of reference lists. Studies were included if they (1) compared the
cognitive performance of adult schizophrenia patients and healthy controls, (2) based
schizophrenia diagnoses on contemporary diagnostic criteria, (3) reported information sufficient to
permit effect size calculation, (4) were reported in English, and (5) reported data for
neuropsychological tests falling into at least 3 distinct cognitive domains. A set of 100 non-
overlapping studies was identified, and effect sizes (Hedge’s g) were calculated for each cognitive
variable.
Results—Consistent with earlier analyses, patients with schizophrenia scored significantly lower
than controls across all cognitive tests and domains (grand mean effect size, g = −1.03). Patients
showed somewhat larger impairments in the domains of processing speed (g = −1.25) and episodic
memory (g = −1.23). Our results also showed few inconsistencies when grouped by geographic
region.
Correspondence: Dwight Dickinson, Clinical Brain Disorders Branch, NIMH, NIH, 10 Center Drive, MSC 1379, Bethesda, Maryland
20892, [email protected], Telephone: (301) 451-2123, Fax: (301) 480-7795.
Contributors
JS, EG, and DD collected and analyzed the data and prepared the first draft of the manuscript. All authors contributed to manuscript
revisions.
Conflict of Interest
The authors declare that they have no conflict of interest.
The authors of this manuscript report no competing interests.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Schaefer et al. Page 2
Conclusions—The present study extends findings from 1980–2006 of a substantial, generalized

cognitive impairment in schizophrenia, demonstrating that this finding has remained robust over
time despite changes in assessment instruments and alterations in diagnostic criteria, and that it
manifests similarly in different regions of the world despite linguistic and cultural differences.
Keywords
schizophrenia; cognition; neuropsychology; meta-analysis; processing speed; memory
1. Introduction
Schizophrenia is a “global” condition in many respects. It impacts widely-acting
neurotransmitter systems (e.g. dopamine, glutatmate, GABA) through subtle changes in
brain microstructure, physiology, and connectivity, and these neurobiological differences
give rise to a variety of affective, cognitive, and psychotic symptoms. Epidemiologically,
the disorder cuts across cultures, regions, and genders, with an estimated lifetime prevalence
of about 1% of the world’s population. Functionally, schizophrenia is associated with
considerable generalized disability, as affected individuals experience low rates of
employment and marriage, decreased somatic health and quality of life, lower levels of
educational achievement, and a marked decrease in life expectancy.
The effect that schizophrenia exerts on cognition can fairly be described as “global” as well.
Resting on evidence from hundreds of studies and thousands of individuals, the finding that
schizophrenia is associated with impairment across a wide range of higher-order cognitive
performance domains is now well-established. Although some reviews highlight particularly
large cognitive deficits in the domains of verbal episodic memory (Heinrichs and Zakzanis,
1998; Reichenberg and Harvey, 2007), executive functioning (Reichenberg and Harvey,
2007), or processing speed (Dickinson et al., 2007), the most consistent finding across
studies has been an overall, generalized impairment across neuropsychological measures
that persists in every clinical state and across patients’ lifespans (Hughes et al., 2003; Albus
et al., 2002; Hill et al., 2004; Hyde et al., 1994). The relationship of cognitive impairment in
schizophrenia to symptom severity is modest (Hughes et al., 2003; Dominguez et al., 2009;
Rund et al., 2004; Ventura et al., 2010). However, cognitive impairment shows consistent
association with indexes of everyday functional capacity. Several studies using a variety of
cognitive assessment strategies have shown consistent associations between cogition and the
UCSD Performance-based Skills Assessment, suggesting a high degree of criterion validity

(Leifker et al., 2010). Cognitive variables are also widely used as intermediate phenotypes in
genetic studies of schizophrenia, as attenuated cognitive deficits are seen even in the
asymptomatic parents and siblings of schizophrenia patients (Dickinson et al., 2007), with
some studies showing reduced impairment in more distant relatives (Glahn et al., 2007;
Toulopoulou et al., 2007; Tuulio-Henriksson et al., 2003).
In 1998, Heinrichs and Zakzanis published the first large-scale meta-analysis of cognitive
deficit findings in schizophrenia, drawing on more than 200 studies conducted between 1980
and 1997 (Heinrichs and Zakzanis, 1998) and documenting an overall mean impairment of
0.92 standard deviations relative to community comparison groups (Heinrichs, 2005).
Various smaller reviews followed, generally focused on a particular cognitive domain

(Aleman et al., 1999) or set of measures (Bokat and Goldberg, 2003). Although narrower in
focus than the Heinrichs review, our 2007 meta-analysis (Dickinson et al., 2007) offered a
general update for studies completed in the decade following Heinrichs & Zakzanis (1998)
and reported a similar outcome. Across measures and samples, this later analysis found a
grand mean effect size of schizophrenia on cognitive performance of 0.98 standard
deviations.
The newest cohort of neuropsychological studies, however, differs from those sampled in
previous meta-analyses in several ways. First, while Heinrichs & Zakzanis’s (1998) seminal
publication included samples of patients diagnosed according to DSM-III and DSM-III-R
criteria, studies conducted within the past decade have virtually all defined schizophrenia
according to criteria laid out in the DSM-IV and DSM-IV-TR. Second, since Heinrichs &
Zakzanis’s (1998) meta-analysis, several canonical neuropsychological measures have been
revised (e.g. WAIS, WMS, CPT), and expert judgment regarding the most appropriate
measures for the study of schizophrenia has evolved, resulting in the emergence of testing
arrays like the MATRICS Consensus Cognitive Battery (Kern et al., 2008; Nuechterlein et
al., 2008). Finally, driven in part by the power requirements of genetics analyses, the most
recent cohort of studies examining cognition in schizophrenia is uniquely international. The
degree to which cognitive deficit findings in schizophrenia are similar across regions that
differ substantially in both language and culture is unknown, however, and some
performance differences have been reported across sites in different areas of the world
(Harvey et al., 2003). As cognitive impairment is considered for inclusion as a possible
specifier for psychotic disorders in ICD-11, the possibility of regional differences in
neuropsychological measurement and/or performance is especially relevant.
A question in the field is whether decreased PubMed references to a “generalized deficit” in

schizophrenia literature in recent years accurately reflects the reduced salience of
generalized impairment for the field (Green et al., 2013). We believe the phenomenon
remains of central relevance, hypothesizing that despite geographic dispersion of research
samples as well as evolving assessment and diagnostic practices, evidence from recent years
would show (1) broad impairment of cognitive performance in schizophrenia (2) a
magnitude and pattern of impairment consistent with what was documented in earlier
reviews, and (3) a similar magnitude and pattern of impairment in data from different
geographic regions. We also investigated the effects of potential moderator variables on
effect size, examining both clinical variables (e.g. medication, symptom ratings, chronicity
of illness) and demographic variables (e.g. participants’ sex, education).
2. Materials and methods

2.1 Study and variable selection
Articles incorporated into this analysis were identified through a series of PubMed searches
using combinations of key words schizophreni*, cogniti*, neurocogniti*, neuropsychologi*,
executive function*, verbal, processing speed, psychomotor speed, perceptual speed, and
attention. The searches were conducted for the period from January 2006 through June
2012. The year 2006 was selected as a start date because it represents the end of the period
reviewed by the most recent meta-analysis of schizophrenia and cognition (3) in the current

literature. In total, nearly 4000 articles were identified in preliminary searches. We retained
a subset of these articles for examination in greater detail based on a review of their titles
and abstracts. Additional publications were also found by searching the reference lists of
these articles, yielding 376 studies in total.
Studies were included in the present analysis if they (1) compared the cognitive performance
of adult schizophrenia patients and healthy controls (and mean ages of both samples were
between 18 and 50 yrs), (2) based schizophrenia diagnoses on contemporary diagnostic
criteria (e.g. DSM-IV, DSM-IV-TR, or ICD-9 or later), (3) reported information sufficient to
permit effect size calculation, (4) were reported in English, and (5) reported data for
neuropsychological tests falling into at least 3 distinct cognitive domains. Of the 376 studies,
we excluded 99 because of insufficient test batteries, 68 because of problems with the
presentation of values, 18 because they did not compare schizophrenia patients and healthy
controls, 17 because patients did not meet DSM-IV criteria for schizophrenia, 11 because
subjects were matched for IQ, 9 because subjects’ mean age fell outside of the acceptable
range, and 2 because of abnormalities in the data due to study methodology (e.g. extreme
flooring or ceiling effects). Where studies appeared to use the same (or overlapping)
samples, we used data from only one of the studies. Accordingly, an additional 52 studies
were eliminated due to overlap concerns, leaving exactly 100 studies that met all meta-
analytic inclusion criteria.
Specific cognitive variables were included in our analysis if they appeared in at least 4 of the
included studies. Altogether, we collected data on 46 cognitive variables, and assembled
them into 10 familiar cognitive domains for presentation. In general, measures were
combined on an individual test by individual test basis, but we also combined very similar
measures in some instances. For example, we combined data across different list-learning
tasks and across different sets of prompts for letter and category fluency tasks. Similarly,
full-battery IQ scores and estimates based on IQ battery short forms were also combined, as
were word reading scores from the Wide Range Achievement and National Adult Reading
Tests.
Finally, we recorded information about a number of potential moderator variables. The

clinical variables included severity/chronicity of illness, the presence and dose of
antipsychotic medication, measures of symptom severity, and measures of global
functioning. We also examined demographic variables including participants’ sex, level of

education, and the geographic location of the sample. Because several of these moderator
variables were inconsistently reported, many moderator analyses had to be conducted in
subsets of studies rather than in the entire group.
2.2. Data analysis

All analyses were performed using the Comprehensive Meta-analysis software package
(Borenstein et al., 2000). Effect sizes for each cognitive variable were calculated as the
mean difference between schizophrenia and healthy control performance divided by the
pooled standard deviation and adjusted for small sample size bias (Hedges and Olkin, 1985).
With few exceptions, the directions of these effect sizes were negative on a study-by-study
level, indicating that schizophrenia patients performed worse than comparison subjects.

These values were then weighted and combined using a conservative random effects model.
We also calculated 95% confidence intervals as well as a χ2 statistic, Q, an indicator of
variability across studies for a given effect size estimate. In our analysis of quantitative
moderator variables, we also calculated the homogeneity statistics Qwithin and Qbetween. The
Qwithin statistic denotes the homogeneity or heterogeneity of studies within moderator
variable subgroups, whereas the Qbetween statistic tests the significance of differences in
effect size magnitude between moderator variable subgroups, similar to an F statistic.
To compare the current findings to past meta-analytic work, we compiled findings from two
other non-overlapping meta-analyses that have addressed the same or comparable cognitive
variables in this population (Heinrichs and Zakzanis, 1998; Dickinson et al., 2007), allowing
us to examine the extent to which cognitive impairment in schizophrenia has remained
stable across time and across changes in testing materials and diagnostic criteria.
Additionally, as the vast majority of samples used in this analysis (N = 92) were from one of
three distinct geographic clusters (closely approximating North America, Europe, and Asia),
we divided these studies into three separate geographic regions to examine the consistency
of generalized cognitive impairment across different cultures and areas of the world, again
calculating Qwithin and Qbetween statistics as measures of within-region and between-region
variability, respectively.
3. Results
3.1 Main meta-analysis
The results of the main meta-analysis are presented in Table 1. Across these studies, data
were analyzed from 9048 patients with schizophrenia and 8814 healthy comparison subjects.
Of our 100 studies, 96 reported the mean ages of both patients and controls. The sample
weighted mean age for the schizophrenia group was 35.1 years (range of study means: 20.1
to 48.5) years, compared with 35.6 years for controls (range: 19.0 to 48.7 years). In the set
of 91 studies reporting participant sex, 49.9% of control participants and 66.8% of probands
were male. The sample-weighted average of years of education across the 70 studies that
provided this information was 12.1 years for patients (range: 9.0 to 14.3) and 13.9 for
controls (range: 10.3 to 16.9). Finally, the average duration of illness for patients according
to the 55 studies reporting this information was 13.2 years (range: 0.8 to 25.0), indicating
considerable chronicity across the study sample as a whole.
Negative effect sizes in Table 1 indicate impairment in the schizophrenia group relative to
healthy controls. As shown in this table, neuropsychological performance was significantly
impaired in the schizophrenia group across all measures tested and all domains, with a grand
mean weighted effect size of g = −1.03. The range of effect sizes for individual variables
grouped by domain is illustrated in Figure 1. In line with our earlier meta-analysis (3), the
largest effect size observed was for the Digit-Symbol Coding test (g = −1.55). The smallest
effect size observed was for the WAIS Information subtest (g = −0.43).
Table 1 also provides weighted average effect sizes for each cognitive domain. Although
different investigators may group cognitive variables differently, such summaries provide an
approximate index of domain specificity. Across domains, impairment among schizophrenia

patients was substantial and fairly consistent, with most measure-by-measure and domain-
level effect sizes falling in the medium to large range (−0.63 to −1.11). Inconsistency from
study to study in terms of which variables and domains were available prevented a formal
test of differences in degree of impairment across domains (e.g., group-by-domain

interaction analyses). Although some effect sizes vary widely within a given domain (e.g.
episodic memory; −0.68 to −1.41), these ranges largely reflect grouping decisions; some
previous studies, for example, have elected to list tests of recognition memory separately
from the rest of the episodic memory domain. Nevertheless, with the magnitude of the grand
mean effect size (−1.03) nearly twice the range of the domain-level effect sizes (−0.68 to
−1.25), it does not appear that the broad cognitive impairment across domains hinges on
variable grouping decisions.
3.2 Moderator variable analyses

As displayed in Table 2, the results from this and two previous meta-analyses indicate that
the profile of cognitive impairment in schizophrenia has remained remarkably stable over
the past several decades. Although the earlier reviews did not provide enough information to
analyze effect size differences statistically, most of the differences from review to review
are small relative to the overall impairment.
Regarding the current analysis, significant Q-values in Table 1 signify greater variation in
cognitive performance from study to study than would be expected by chance for 38 of the
46 individual effect sizes. We performed a series of analyses to examine the influence of
moderator variables on effect size variability within the schizophrenia sample. Our first
analysis examined the effect of geographic region on neuropsychological functioning (Table
3). Results indicated that the grand mean effect size, reflecting overall impairment, was
strikingly consistent across the three regions examined (Qbetween = 0.21, p = 0.98), a finding
that also extended to the measure-by-measure analyses, with the exception of Vocabulary
(Qbetween = 8.94, p = 0.01) and Trails B (Qbetween = 21.54, p = 8.13 × 10−5) tests.
Meta-regressions for age and education effects on impairment effect size were confounded
in these data. Across studies, as the schizophrenia sample mean age increased, so did the
degree to which the schizophrenia sample was relatively older than the control sample (K =
96, r = .376, p = 8.02 × 10−5), making it difficult to separate within group age effects from
between groups age-disparity effects. Similarly, across studies, the mean years of education
achieved by controls was highly correlated with the magnitude of the difference in years of
education between controls and patients (K = 70, r = .686, p < 1 × 10−5). In regard to sex,
the effect sizes derived from a given study tended to be larger in studies reporting a greater
percentage of male patients (K = 92; z = 2.45, p = 0.01).
Among clinical variables, we found that neither schizophrenia age of onset (K = 39; z =
−0.36, p = 0.72), duration of illness (K = 55; z = 0.42, p = 0.68), nor CPZE (K = 28; z =
−0.11, p = 0.91) were significantly related to the magnitude of impairment observed.
Consistent with the literature (e.g. 8), after excluding an outlying, medication-naïve, first
episode sample from the analysis (115), we found no significant relationship between
patient’s scores on the PANSS positive symptom scale and cognition (K = 40, z = −0.01, p =
0.99). Somewhat surprisingly, we also observed no significant relationship between

impairment effect size and patient’s scores on both the PANSS negative symptom scale (K =
41; z = 0.44, p = 0.66) and measures of total symptomatology, such as patient’s PANSS
Total Scores (K = 24; z = −1.04, p = 0.30), or scores on the BPRS (K = 15; z = −0.02, p =
0.98). In a small selection of studies reporting the data, cognitive impairment was not
significantly associated with patients’ global functioning (GAF) scores (K = 11; z = −0.72, p
= 0.47).
4. Discussion
The current analysis updates the evidence of broad cognitive impairment in schizophrenia,
again revealing moderate to severe impairment in people with schizophrenia relative to
controls across all neuropsychological measures studied, and somewhat larger cognitive
differences in the domains of processing speed and episodic memory (see Figure 1). These
findings are quite consistent with earlier reviews. Remarkably, despite significant changes in
diagnostic criteria, assessment materials and practice, and sample ascertainment, the
observed variation in the overall, grand mean effect size of cognitive impairment in
schizophrenia over three decades of research is about 0.1 standard deviations, less than 10%
of the total impairment observed.
Geographic variation in the pattern of cognitive impairment in schizophrenia has not been
examined in previous reviews. Our analyses indicate that the region of the world in which a
cognition study is conducted has little impact on the effect sizes reported. The average grand
means across groups of studies from Asia, Europe, and the United States are strikingly
consistent (ranging from 1.02 to 1.08), despite substantial geographic, cultural, and
linguistic differences across groups. Similar consistency can also be observed at the level of
individual measures, with the exception of Vocabulary and Trails B tests. The reason for the
differences by region in Vocabulary and Trails B performance is unclear, but variation in
Vocabulary performance might relate in part to varying levels of multilingualism among the
samples studied (Paez et al., 2006; Windsor and Kohnert, 2006). Variation in Trails B, on
the other hand, may be partially attributable to differences in testing stimuli used in different
countries (e.g. some Chinese versions of the test replace the letters with corresponding
Chinese characters).
In an attempt to explain the substantial effect size heterogeneity observed in our main meta-
analysis (see Table 1), we also examined several other moderator variables. Consistent with
studies that report poorer cognitive functioning in male schizophrenia patients relative to
females (Vaskinn et al., 2011), we found that studies with larger percentages of male
patients tended to report larger effect sizes. In addition, we found that cognitive impairment
was relatively unrelated to most measures of symptomatology, somewhat in contrast to
studies highlighting modest but statistically reliable associations between cognition and
negative or disorganized symptoms, including a recent meta-analysis on the topic
(Dominguez et al., 2009).
Interestingly, our moderator analyses found no significant relationship between duration of

illness and cognitive impairment. This finding is in line with data from longitudinal studies.
A recent meta-analysis examining cognition in first-episode psychosis concluded that the

degree of cognitive change over time tends to be similar in cases and controls (Bozikas and
Andreou, 2011). Although other studies have shown an association between cognition and
indexes of everyday functioning (Green et al., 2000, 2004, 2006), including the Global
Assessment of Functioning (GAF; Karilampi et al., 2011), we found no significant

association between patient GAF scores and cognitive ability. This null finding may reflect
the relatively small number of studies reporting GAF data in our sample (K = 11) or the
mixture of symptom severity with everyday functioning in GAF ratings.
As with all meta-analyses, the findings reported in this paper are shaped by study selection
methods, analytical methods, and the information made available to researchers in the
studies selected for review. One difference between this review and some previous analyses
is that we elected to include only studies that included at least one cognitive measure across
at least three distinct domains. This resulted in a high representation in our study sample of
“full neuropsychological battery” studies. We imposed this limitation because we judged
such studies most likely to yield consistent, unbiased information about cognitive
performance across measures. Despite this limitation, the present analysis is, as measured by
combined sample size, the largest of its kind and results show a remarkable degree of
consistency with past reviews.
In summary, this analysis of studies using contemporary neuropsychological tests and

measures adds to the ample evidence of generalized cognitive impairment in schizophrenia.
This impairment is probably the end-product of years of compromised neurodevelopment
(Weinberger and Levitt, 2011) – and may be etiologically variable from person to person.
Newer investigative methods from the cognitive and affective neuroscience literature will
test whether this broad impairment can be divided into separable component processes
(Carter and Barch, 2007). In its enthusiasm for these methods, the field has sometimes
shown an inclination to question whether the cognitive impairment in this disorder is truly as
generalized as it appears (Green et al., 2013). We would argue that the evidence for
generalized cognitive impairment in schizophrenia – spanning decades and many thousands
of research participants from around the globe – has reached the point of being
overwhelming. Generalized cognitive impairment may present an unwieldy target for study,
but it remains the clearest cognitive signal in schizophrenia research and a fundamental
challenge for investigators trying to understand and treat this illness.
Acknowledgments
The authors would like to extend their heartfelt thanks to Jody Mozersky for her hard work on the meta-analysis
article database.
Funding
This work was supported by the Division of Intramural Research Programs, National Institute of Mental Health,
National Institutes of Health (NIH), through funding to the Weinberger Lab, and the Lieber Institute for Brain
Development, Baltimore, Maryland (http://www.libd.org).
Role of Funding Source
Support for this research was provided by the National Institute of Mental Health Intramural Research Program via
direct funding to the Weinberger Lab.

References
(studies indicated with an asterisk were included in the main meta-analysis)
*. Abbott CC, Merideth F, Ruhl D, Yang Z, Clark VP, Calhoun VD, Hanlon FM, Mayer AR. Auditory
orienting and inhibition of return in schizophrenia: A functional magnetic resonance imaging
study. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 37(1):161–168. [PubMed: 22230646]
*. Abdel-Hamid M, Lehmkamper C, Sonntag C, Juckel G, Daum I, Brune M. Theory of mind in
schizophrenia: the role of clinical symptomatology and neurocognition in understanding other
people’s thoughts and intentions. Psychiatry Res. 2009; 165(1–2):19–26. [PubMed: 19073346]
*. Ahn WY, Rass O, Fridberg DJ, Bishara AJ, Forsyth JK, Breier A, Busemeyer JR, Hetrick WP,
Bolbecker AR, O’Donnell BF. Temporal discounting of rewards in patients with bipolar disorder
and schizophrenia. J Abnorm Psychol. 2011; 120(4):911–921. [PubMed: 21875166]
Albus M, Hubmann W, Scherer J, Dreikorn B, Hecht S, Sobizack N, Mohr F. A prospective 2-year
follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch
Psychiatry Clin Neurosci. 2002; 252(6):262–267. [PubMed: 12563534]
Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis.
Am J Psychiatry. 1999; 156(9):1358–1366. [PubMed: 10484945]
*. Amann B, Gomar JJ, Ortiz-Gil J, McKenna P, Sans-Sansa B, Sarro S, Moro N, Madre M, Landin-
Romero R, Vieta E, Giokolea JM, Salvador R, Pomarol-Clotet E. Executive dysfunction and
memory impairment in schizoaffective disorder: a comparison with bipolar disorder,
schizophrenia and healthy controls. Psychol Med. 2012:1–9.
*. Ammari N, Heinrichs RW, Miles AA. An investigation of 3 neurocognitive subtypes in

schizophrenia. Schizophr Res. 2010; 121(1–3):32–38. [PubMed: 20646913]
*. Anselmetti S, Cavallaro R, Bechi M, Angelone SM, Ermoli E, Cocchi F, Smeraldi E.
Psychopathological and neuropsychological correlates of source monitoring impairment in
schizophrenia. Psychiatry Res. 2007; 150(1):51–59. [PubMed: 17289157]
*. Azizian A, Yeghiyan M, Ishkhanyan B, Manukyan Y, Khandanyan L. Clinical validity of the
Repeatable Battery for the Assessment of Neuropsychological Status among patients with
schizophrenia in the Republic of Armenia. Arch Clin Neuropsychol. 2011; 26(2):89–97.
[PubMed: 21177761]
*. Barch DM, Yodkovik N, Sypher-Locke H, Hanewinkel M. Intrinsic motivation in schizophrenia:
relationships to cognitive function, depression, anxiety, and personality. J Abnorm Psychol.
2008; 117(4):776–787. [PubMed: 19025225]
*. Barrantes-Vidal N, Aguilera M, Campanera S, Fatjo-Vilas M, Guitart M, Miret S, Valero S, Fananas
L. Working memory in siblings of schizophrenia patients. Schizophr Res. 2007; 95(1–3):70–75.
[PubMed: 17628433]
*. Berna F, Bennouna-Greene M, Potheegadoo J, Verry P, Conway MA, Danion JM. Impaired ability
to give a meaning to personally significant events in patients with schizophrenia. Conscious
Cogn. 2011; 20(3):703–711. [PubMed: 21459619]
*. Bhatia T, Garg K, Pogue-Geile M, Nimgaonkar VL, Deshpande SN. Executive functions and
cognitive deficits in schizophrenia: comparisons between probands, parents and controls in India.
J Postgrad Med. 2009; 55(1):3–7. [PubMed: 19242070]
*. Boeker H, Kleiser M, Lehman D, Jaenke L, Bogerts B, Northoff G. Executive dysfunction, self, and
ego pathology in schizophrenia: an exploratory study of neuropsychology and personality.
Compr Psychiatry. 2006; 47(1):7–19. [PubMed: 16324897]
Bokat CE, Goldberg TE. Letter and category fluency in schizophrenic patients: a meta-analysis.
Schizophr Res. 2003; 64(1):73–78. [PubMed: 14511803]
*. Bonner-Jackson A, Barch DM. Strategic manipulations for associative memory and the role of
verbal processing abilities in schizophrenia. J Int Neuropsychol Soc. 2011; 17(5):796–806.
[PubMed: 21729401]
Borenstein, M.; Hedges, LV.; Higgens, J.; Rothstein, H. Comprehensive Meta-analysis. Biostat;
Englewood, NJ: 2000.

Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic
review of the literature. Aust N Z J Psychiatry. 2011; 45(2):93–108. [PubMed: 21320033]
*. Bozikas VP, Kosmidis MH, Peltekis A, Giannakou M, Nimatoudis I, Karavatos A, Fokas K,
Garyfallos G. Sex differences in neuropsychological functioning among schizophrenia patients.

Aust N Z J Psychiatry. 2010; 44(4):333–341. [PubMed: 20050721]
*. Brissos S, Dias VV, Carita AI, Martinez-Aran A. Quality of life in bipolar type I disorder and
schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res. 2008; 160(1):
55–62. [PubMed: 18485488]
*. Brissos S, Dias VV, Soeiro-de-Souza MG, Balanza-Martinez V, Kapczinski F. The impact of a
history of psychotic symptoms on cognitive function in euthymic bipolar patients: a comparison
with schizophrenic patients and healthy controls. Rev Bras Psiquiatr. 2011; 33(4):353–361.
[PubMed: 22189924]
Carter CS, Barch DM. Cognitive neuroscience-based approaches to measuring and improving
treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007;
33(5):1131–1137. [PubMed: 17630405]
*. Chan WY, Chia MY, Yang GL, Woon PS, Sitoh YY, Collinson SL, Nowinski WL, Sim K. Duration
of illness, regional brain morphology and neurocognitive correlates in schizophrenia. Ann Acad
Med Singapore. 2009; 38(5):388–388. [PubMed: 19521637]
*. Chia MY, Chan WY, Chua KY, Lee H, Lee J, Lee R, Lim C, Tay E, Woon PS, Keefe RS, Sim K.
The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of
cognitive functioning in Asian patients with schizophrenia. Psychiatry Res. 2010; 178(1):33–38.
[PubMed: 20451258]
*. Chino B, Mizuno M, Nemoto T, Yamashita C, Kashima H. Relation between social functioning and
neurocognitive test results using the Optional Thinking Test in schizophrenia. Psychiatry Clin
Neurosci. 2006; 60(1):63–69. [PubMed: 16472360]
*. Chirio M, Krebs MO, Waismann R, Vanelle JM, Olie JP, Amado I. Attention and visual orienting in
siblings, schizophrenic patients, and controls: impairment in attentional disengagement. J Clin
Exp Neuropsychol. 2010; 32(5):449–454. [PubMed: 19763996]
*. Chung S, Chung HY, Jung J, Chang JK, Hong JP. Association among aggressiveness,
neurocognitive function, and the Val66Met polymorphism of brain-derived neurotrophic factor
gene in male schizophrenic patients. Compr Psychiatry. 2010; 51(4):367–372. [PubMed:
20579509]
*. Cobia DJ, Csernansky JG, Wang L. Cortical thickness in neuropsychologically near-normal
schizophrenia. Schizophr Res. 2011; 133(1–3):68–76. [PubMed: 21981933]
*. Cuesta MJ, Peralta V, Zarzuela A. Empirical validation of competing definitions of schizophrenia: a
poly-diagnostic study of cognitive impairment in non-affective psychosis. Schizophr Res. 2007;
95(1–3):39–47. [PubMed: 17651943]
*. Dichter GS, van der Stelt O, Boch JL, Belger A. Relations among intelligence, executive function,
and P300 event related potentials in schizophrenia. J Nerv Ment Dis. 2006; 194(3):179–187.
[PubMed: 16534435]
Dickinson D, Goldberg TE, Gold JM, Elvevag B, Weinberger DR. Cognitive factor structure and
invariance in people with schizophrenia, their unaffected siblings, and controls. Schizophr Bull.
2011; 37(6):1157–1167. [PubMed: 20351040]
Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit
symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;
64(5):532–542. [PubMed: 17485605]
Dominguez MD, Viechtbauer W, Simons CJP, van Os J, Krabbendam L. Are Psychotic
Psychopathology and Neurocognition Orthogonal? A Systematic Review of Their Associations.
Psychological Bull. 2009; 135(1):157–171.
*. Donohoe G, Walters J, Morris DW, Quinn EM, Judge R, Norton N, Giegling I, Hartmann AM,
Moller HJ, Muglia P, Williams H, Moskvina V, Peel R, O’Donoghue T, Owen MJ, O’Donovan
MC, Gill M, Rujescu D, Corvin A. Influence of NOS1 on verbal intelligence and working
memory in both patients with schizophrenia and healthy control subjects. Arch Gen Psychiatry.
2009; 66(10):1045–1054. [PubMed: 19805695]

*. Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and
first episode of psychosis. Schizophr Res. 2007; 93(1–3):266–277. [PubMed: 17467955]
*. Egan GJ, Hasenkamp W, Wilcox L, Green A, Hsu N, Boshoven W, Lewison B, Keyes MD, Duncan
E. Declarative memory and WCST-64 performance in subjects with schizophrenia and healthy
controls. Psychiatry Res. 2011; 188(2):191–196. [PubMed: 21481945]
Egan MF, Goldberg TE, Gscheidle T, Weirich M, Rawlings R, Hyde TM, Bigelow L, Weinberger DR.
Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry.
2001; 50(2):98–107. [PubMed: 11527000]
*. Ehrlich S, Brauns S, Yendiki A, Ho BC, Calhoun V, Schulz SC, Gollub RL, Sponheim SR.
Associations of cortical thickness and cognition in patients with schizophrenia and healthy
controls. Schizophr Bull. 2012; 38(5):1050–1062. [PubMed: 21436318]
*. Flashman LA, Roth RM, Pixley HS, Cleavinger HB, McAllister TW, Vidaver R, Saykin AJ. Cavum
septum pellucidum in schizophrenia: clinical and neuropsychological correlates. Psychiatry Res.
2007; 154(2):147–155. [PubMed: 17291728]
*. Freedman D, Bao Y, Kremen WS, Vinogradov S, McKeague IW, Brown AS. Birth Weight and
Neurocognition in Schizophrenia Spectrum Disorders. Schizophr Bull. 2013; 39(3):592–600.
[PubMed: 22378899]
*. Giakoumaki SG, Roussos P, Pallis EG, Bitsios P. Sustained attention and working memory deficits
follow a familial pattern in schizophrenia. Arch Clin Neuropsychol. 2011; 26(7):687–695.
[PubMed: 21813556]
Glahn DC, Almasy L, Blangero J, Burk GM, Estrada J, Peralta JM, Meyenberg N, Castro MP, Barrett
J, Nicolini H, Raventos H, Escamilla MA. Adjudicating neurocognitive endophenotypes for

schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B(2):242–249. [PubMed:
17034022]
*. Gold JM, Hahn B, Zhang WW, Robinson BM, Kappenman ES, Beck VM, Luck SJ. Reduced
capacity but spared precision and maintenance of working memory representations in
schizophrenia. Arch Gen Psychiatry. 2010; 67(6):570–577. [PubMed: 20530006]
*. Gonzalez-Blanch C, Crespo-Facorro B, Alvarez-Jimenez M, Rodriguez-Sanchez JM, Pelayo-Teran
JM, Perez-Iglesias R, Vazquez-Barquero JL. Cognitive dimensions in first-episode schizophrenia
spectrum disorders. J Psychiatr Res. 2007; 41(11):968–977. [PubMed: 17049561]
Green MF, Horan WP, Sugar CA. Has the generalized deficit become the generalized criticism?
Schizophr Bull. 2013; 39(2):257–262. [PubMed: 23236079]
Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in
schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2006; 26:119–136. [PubMed:
10755673]
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in
schizophrenia: implications for MATRICS. Schizophr Res. 2004; 72(1):41–51. [PubMed:
15531406]
Green, MF.; Kern, RS.; Robertson, M.; Sergi, M.; Kee, K. Relevance of neurocognitive deficits for
functional outcome in schizophrenia. In: Sharma, T.; Harvey, P., editors. Cognition in
Schizophrenia. Oxford University Press; Oxford, England: 2000. p. 178-192.

*. Halari R, Mehrotra R, Sharma T, Ng V, Kumari V. Cognitive impairment but preservation of sexual
dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Res. 2006; 141(2):129–
139. [PubMed: 16427141]
*. Hartberg CB, Lawyer G, Nyman H, Jonsson EG, Haukvik UK, Saetre P, Bjerkan PS, Andreassen
OA, Hall H, Agartz I. Investigating relationships between cortical thickness and cognitive
performance in patients with schizophrenia and healthy adults. Psychiatry Res. 2010; 182(2):
123–133. [PubMed: 20456929]
Harvey PD, Artiola i Fortuny L, Vester-Blockland E, De Smedt G. Cross-national cognitive
assessment in schizophrenia clinical trials: a feasibility study. Schizophr Res. 2003; 59(2–3):243–
251. [PubMed: 12414081]
*. Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Iwase M, Iike N, Azechi M, Ikezawa K, Takaya M,
Takahashi H, Yamamori H, Okochi T, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka
T, Kudo T, Kazui H, Iwata N, Takeda M. The impact of a genome-wide supported psychosis

variant in the ZNF804A gene on memory function in schizophrenia. Am J Med Genet B

Neuropsychiatr Genet. 2010; 153B(8):1459–1464. [PubMed: 20957649]
Hedges, LV.; Olkin, I. Statistical Methods for Meta-analysis. Academic Press; Orlando, FL: 1985.
Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol. 2005; 60(3):229–242.

[PubMed: 15796677]
Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the
evidence. Neuropsychol. 1998; 12(3):426–445.
*. Hill SK, Reilly JL, Harris MS, Rosen C, Marvin RW, Deleon O, Sweeney JA. A comparison of
neuropsychological dysfunction in first-episode psychosis patients with unipolar depression,
bipolar disorder, and schizophrenia. Schizophr Res. 2009; 113(2–3):167–175. [PubMed:
19450952]
Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal
studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia.
*. Holthausen EA, Wiersma D, Cahn W, Kahn RS, Dingemans PM, Schene AH, van den Bosch RJ.
Predictive value of cognition for different domains of outcome in recent-onset schizophrenia.
Psychiatry Res. 2007; 149(1–3):71–80. [PubMed: 17141329]
*. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, Tsukue R, Anami K,
Hirabayashi N, Harada S, Saitoh O, Iwase M, Kajimoto O, Takeda M, Okabe S, Kunugi H.
Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006; 86(1–
3):138–146. [PubMed: 16793238]
*. Hu M, Chen J, Li L, Zheng Y, Wang J, Guo X, Wu R, Zhao J. Semantic fluency and executive

functions as candidate endophenotypes for the early diagnosis of schizophrenia in Han Chinese.
Neurosci Lett. 2011; 502(3):173–177. [PubMed: 21827833]
*. Huddy VC, Aron AR, Harrison M, Barnes TR, Robbins TW, Joyce EM. Impaired conscious and
preserved unconscious inhibitory processing in recent onset schizophrenia. Psychol Med. 2009;
39(6):907–916. [PubMed: 18796175]
Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, O’Neil S, Mathew V, Sharma T.
Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res.
2003; 59(2–3):137–146. [PubMed: 12414070]
Hyde TM, Nawroz S, Goldberg TE, Bigelow LB, Strong D, Ostrem JL, Weinberger DR, Kleinman JE.
Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry. 1994; 164(4):
494–500. [PubMed: 8038938]
*. Jahshan C, Heaton RK, Golshan S, Cadenhead KS. Course of neurocognitive deficits in the
prodrome and first episode of schizophrenia. Neuropsychol. 2010; 24(1):109–120.
*. Karilampi U, Helldin L, Archer T. Cognition and global assessment of functioning in male and
female outpatients with schizophrenia spectrum disorders. J Nerv Ment Dis. 2011; 199(7):445–
448. [PubMed: 21716056]
*. Katz N, Tadmor I, Felzen B, Hartman-Maeir A. The Behavioural Assessment of the Dysexecutive
Syndrome (BADS) in schizophrenia and its relation to functional outcomes. Neuropsychol
Rehabil. 2007; 17(2):192–205. [PubMed: 17454693]

*. Kern RS, Hartzell AM, Izaguirre B, Hamilton AH. Declarative and nondeclarative memory in
schizophrenia: What is impaired? What is spared? J Clin Exp Neuropsychol. 2010; 32(9):1017–
1027. [PubMed: 20446142]
*. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-
Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS Consensus Cognitive
Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008; 165(2):214–220.
[PubMed: 18172018]
*. Kiang M, Light GA, Prugh J, Coulson S, Braff DL, Kutas M. Cognitive, neurophysiological, and
functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol
Soc. 2007; 13(4):653–663. [PubMed: 17521483]
*. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma
and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012; 71(10):873–880.
[PubMed: 22361076]

*. Kitis A, Akdede BB, Alptekin K, Akvardar Y, Arkar H, Erol A, Kaya N. Cognitive dysfunctions in
patients with obsessive-compulsive disorder compared to the patients with schizophrenia
patients: relation to overvalued ideas. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(1):
254–261. [PubMed: 16914246]

*. Klingberg S, Wittorf A, Sickinger S, Buchkremer G, Wiedemann G. Course of cognitive
functioning during the stabilization phase of schizophrenia. J Psychiatr Res. 2008; 42(4):259–
267. [PubMed: 17400252]
*. Konstantakopoulos G, Ploumpidis D, Oulis P, Patrikelis P, Soumani A, Papadimitriou GN, Politis
AM. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr Res.
2011; 133(1–3):193–198. [PubMed: 21788116]
*. Kumar D, Nizamie SH, Jahan M. Activity-based prospective memory in schizophrenia. Clin
Neuropsychol. 2008; 22(3):497–506. [PubMed: 17853129]
*. Laes JR, Sponheim SR. Does cognition predict community function only in schizophrenia? : a study
of schizophrenia patients, bipolar affective disorder patients, and community control subjects.
*. Laywer G, Nyman H, Agartz I, Arnborg S, Jonsson EG, Sedvall GC, Hall H. Morphological
correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC
Psychiatry. 2006; 6:31. [PubMed: 16901336]
*. Lee KH, Bhaker RS, Mysore A, Parks RW, Birkett PB, Woodruff PW. Time perception and its
neuropsychological correlates in patients with schizophrenia and in healthy volunteers.
Psychiatry Res. 2009; 166(2–3):174–183. [PubMed: 19278734]
Leifker FR, Bowie CR, Harvey PD. Psychometric properties of performance-based measurements of
functional capacity: Test–retest reliability, practice effects, and potential sensitivity to change.
Schizophr Res. 2010; 119 (1–3):246–252. [PubMed: 20399613]
*. Lennertz L, Rujescu D, Wagner M, Frommann I, Schulze-Rauschenbach S, Schuhmacher A,
Landsberg MW, Franke P, Moller HJ, Wolwer W, Gaebel W, Hafner H, Maier W, Mossner R.
Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in
schizophrenia patients. Neuropsychobiol. 2011; 63(3):131–136.
*. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band
oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol
Psychiatry. 2006; 60(11):1231–1240. [PubMed: 16893524]
*. Loewenstein DA, Czaja SJ, Bowie CR, Harvey PD. Age-associated differences in cognitive
performance in older patients with schizophrenia: a comparison with healthy older adults. Am J
Geriatr Psychiatry. 2012; 20(1):29–40. [PubMed: 22130385]
*. Lorente-Rovira E, Santos-Gomez JL, Moro M, Villagran JM, McKenna PJ. Confabulation in
schizophrenia: a neuropsychological study. J Int Neuropsychol Soc. 2010; 16(6):1018–1026.
[PubMed: 20630120]
*. Majorek K, Wolfkuhler W, Kuper C, Saimeh N, Juckel G, Brune M. “Theory of mind” and
executive functioning in forensic patients with schizophrenia. J Forensic Sci. 2009; 54(2):469–
473. [PubMed: 19187455]
*. Manning V, Betteridge S, Wanigaratne S, Best D, Strang J, Gossop M. Cognitive impairment in

dual diagnosis inpatients with schizophrenia and alcohol use disorder. Schizophr Res. 2009;
114(1–3):98–104. [PubMed: 19540724]
*. Mazza M, Di Michele V, Pollice R, Casacchia M, Roncone R. Pragmatic language and theory of
mind deficits in people with schizophrenia and their relatives. Psychopathology. 2008; 41(4):
254–263. [PubMed: 18441527]
*. Meijer J, Simons CJ, Quee PJ, Verweij K. Cognitive alterations in patients with non-affective
psychotic disorder and their unaffected siblings and parents. Acta Psychiatrica Scand. 2012;
125(1):66–76.
*. Morrens M, Hulstijn W, Van Hecke J, Peuskens J, Sabbe BG. Sensorimotor and cognitive slowing
in schizophrenia as measured by the Symbol Digit Substitution Test. J Psychiatry Res. 2006;
40(3):200–206.
*. Moser C, Krieg JC, Zihl J, Lautenbacher S. Attention and memory deficits in schizophrenia: the role
of symptoms of depression. Cogn Behav Neurol. 2006; 19(3):150–156. [PubMed: 16957493]

*. Nestor PG, Niznikiewicz M, McCarley RW. Distinct contribution of working memory and social
comprehension failures in neuropsychological impairment in schizophrenia. J Nerv Ment Dis.
2010; 198(3):206–212. [PubMed: 20215998]
*. Ngoma M, Vansteelandt K, Delespaul P, Krabbendam L, Miezi SM, Peuskens J. Cognitive deficits

in nonaffective functional psychoses: a study in the Democratic Republic of Congo. Psychiatry
Res. 2010; 180(2–3):86–92. [PubMed: 20494461]
*. Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T,
Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M. A randomized, double-blind,
placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J
Clin Psychopharmacol. 2012; 32(5):593–601. [PubMed: 22926591]
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese
FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman
LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus
Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165(2):
203–213. [PubMed: 18172019]
*. Ojeda N, Pena J, Sanchez P, Elizagarate E, Ezcurra J. Processing speed mediates the relationship
between verbal memory, verbal fluency, and functional outcome in chronic schizophrenia.
Schizophr Res. 2008; 101(1–3):225–233. [PubMed: 18261885]
*. Owens SF, Rijsdijk F, Picchioni MM, Stahl D, Nenadic I, Murray RM, Toulopoulou T. Genetic
overlap between schizophrenia and selective components of executive function. Schizophr Res.
2011; 127(1–3):181–187. [PubMed: 21056927]
Paez M, Rinaldi C. Predicting English Word Reading Skills for Spanish-Speaking Students in First
Grade. Top Lang Disord. 2006; 26(4):338–350. [PubMed: 20396623]

*. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState
Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J
Clin Exp Neuropsychol. 2009; 31(7):848–859. [PubMed: 19142774]
*. Polimeni JO, Campbell DW, Gill D, Sawatzky BL, Reiss JP. Diminished humour perception in
schizophrenia: relationship to social and cognitive functioning. J Psychiatr Res. 2010; 44(7):434–
440. [PubMed: 19892368]
*. Pradhan BK, Chakrabarti S, Nehra R, Mankotia A. Cognitive functions in bipolar affective disorder
and schizophrenia: comparison. Psychiatry Clin Neurosci. 2008; 62(5):515–525. [PubMed:
18950370]
*. Premkumar P, Fannon D, Kuipers E, Cooke MA, Simmons A, Kumari V. Association between a
longer duration of illness, age and lower frontal lobe grey matter volume in schizophrenia. Behav
Brain Res. 2008; 193(1):132–139. [PubMed: 18586335]
Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: Integration of
performance-based and brain imaging findings. Psychol Bull. 2007; 133(5):833–858. [PubMed:
17723032]
Rund BR, Melle I, Friis S, Larsen TK, Midboe LJ, Opjordsmoen S, Simonsen E, Vaglum P,
McGlashan T. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms,

premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry. 2004; 161(3):466–
472. [PubMed: 14992972]
*. Sanchez-Morla EM, Barabash A, Martinez-Vizcaino V, Tabares-Seisdedos R, Balanza-Martinez V,
Cabranes-Diaz JA, Baca-Baldomero E, Gomez JL. Comparative study of neurocognitive function
in euthymic bipolar patients and stabilized schizophrenic patients. Psychiatry Res. 2009; 169(3):
220–228. [PubMed: 19758705]
*. Savla GN, Twamley EW, Thompson WK, Delis DC, Jeste DV, Palmer BW. Evaluation of specific
executive functioning skills and the processes underlying executive control in schizophrenia. J
Int Neuropsychol Soc. 2011; 17(1):14–23. [PubMed: 21062522]
*. Scholes KE, Martin-Iverson MT. Cannabis use and neuropsychological performance in healthy
individuals and patients with schizophrenia. Psychol Med. 2010; 40(10):1635–1646. [PubMed:
20018124]

*. Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F,

Gascon J, Soler-Insa PA, Menchon JM, Junque C, Keefe RS. Spanish validation of the Brief
Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy
controls. Eur Psychiatry. 2011; 26(2):69–73. [PubMed: 20435446]

*. Segarra N, Bernardo M, Valdes M, Caldu X, Falcon C, Rami L, Bargallo N, Parramon G, Junque C.
Cerebellar deficits in schizophrenia are associated with executive dysfunction. Neuroreport.
2008; 19(15):1513–1517. [PubMed: 18797308]
*. Sevik AE, Anil Yagcioglu AE, Yagcioglu S, Karahan S, Gurses N, Yildiz M. Neuropsychological
performance and auditory event related potentials in schizophrenia patients and their siblings: a
family study. Schizophr Res. 2011; 130(1–3):195–202. [PubMed: 21592733]
*. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A. Iowa
gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-
occurring cannabis use disorders. Schizophr Res. 2007; 92(1–3):74–84. [PubMed: 17379482]
*. Silver H, Goodman C, Bilker WB, Knoll G, Gur R, Povar G. Suboptimal processing strategy and
working-memory impairments predict abstraction deficit in schizophrenia. J Clin Exp
Neuropsychol. 2007; 29(8):823–830. [PubMed: 18030633]
*. Stirling J, Hellewell J, Blakey A, Deakin W. Thought disorder in schizophrenia is associated with
both executive dysfunction and circumscribed impairments in semantic function. Psychol Med.
2006; 36(4):475–484. [PubMed: 16403241]
*. Suazo V, Diez A, Martin C, Ballesteros A, Casado P, Martin-Loeches M, Molina V. Elevated noise
power in gamma band related to negative symptoms and memory deficit in schizophrenia. Prog
Neuropsychopharmacol Biol Psychiatry. 2012; 38(2):270–275. [PubMed: 22549114]
*. Tabares-Seisdedos R, Balanza-Martinez V, Sanchez-Moreno J, Martinez-Aran A, Salazar-Fraile J,

Selva-Vera G, Rubio C, Mata I, Gomez-Beneyto M, Vieta E. Neurocognitive and clinical
predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year
follow-up. J Affect Disord. 2008; 109(3):286–299. [PubMed: 18289698]
*. Takei K, Yamasue H, Abe O, Yamada H, Inoue H, Suga M, Muroi M, Sasaki H, Aoki S, Kasai K.
Structural disruption of the dorsal cingulum bundle is associated with impaired Stroop
performance in patients with schizophrenia. Schizophr Res. 2009; 114(1–3):119–127. [PubMed:
19505800]
*. Thornton AE, Boudreau VG, Griffiths SY, Woodward TS, Fawkes-Kirby T, Honer WG. The impact
of monetary reward on memory in schizophrenia spectrum disorder. Neuropsychol. 2007; 21(5):
631–645.
*. Thuaire F, Izaute M, Bacon E. Evidence of some strategic preservation of episodic learning in
patients with schizophrenia. Psychiatry Res. 2012; 195(1–2):27–31. [PubMed: 21851990]
*. Torniainen M, Suvisaari J, Partonen T, Castaneda AE, Kuha A, Suokas J, Perala J, Saarni SI,
Lonnqvist J, Tuulio-Henriksson A. Cognitive impairments in schizophrenia and schizoaffective
disorder: relationship with clinical characteristics. J Nerv Ment Dis. 2012; 200(4):316–322.
[PubMed: 22456585]
Toulopoulou T, Picchioni M, Rijsdijk F, Hua-Hall M, Ettinger U, Sham P, Murray R. Substantial
genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples.
Arch Gen Psychiatry. 2007; 64(12):1348–1355. [PubMed: 18056542]
*. Trivedi JK, Goel D, Sharma S, Singh AP, Sinha PK, Tandon R. Cognitive functions in stable
schizophrenia & euthymic state of bipolar disorder. Indian J Med Res. 2007; 126(5):433–439.
[PubMed: 18160747]
Tuulio-Henriksson A, Arajarvi R, Partonen T, Haukka J, Varilo T, Schreck M, Cannon T, Lonnqvist J.
Familial loading associates with impairment in visual span among healthy siblings of
schizophrenia patients. Biol Psychiatry. 2003; 54(6):623–628. [PubMed: 13129657]
*. Vaskinn A, Sundet K, Simonsen C, Hellvin T, Melle I, Andreassen OA. Sex differences in
neuropsychological performance and social functioning in schizophrenia and bipolar disorder.
Neuropsychol. 2011; 25(4):499–510.
Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. Disorganization and reality distortion in
schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive
deficits. Schizophr Res. 2010; 121(1–3):1–14. [PubMed: 20579855]

*. Wang Q, Vassos E, Deng W, Ma X, Hu X, Murray RM, Collier DA, Li T. Factor structures of the
neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their
relatives and controls. Aust N Z J Psychiatry. 2010; 44(2):109–119. [PubMed: 20113299]
*. Wang X, Yao S, Kirkpatrick B, Shi C, Yi J. Psychopathology and neuropsychological impairments

in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res. 2008; 158(2):195–205.
[PubMed: 18243336]
*. Waters FA, Badcock JC, Dragovic M, Jablensky A. Neuropsychological functioning in
schizophrenia patients with first-rank (passivity) symptoms. Psychopathology. 2009; 42(1):47–
58. [PubMed: 19127100]
Weinberger, DR.; Levitt, P. The neurodevelopmental origins of schizophrenia. In: Weinberger, DR.;
Harrison, PE., editors. Schizophrenia. 3. Wiley-Blackwell; Oxford, England: 2011. p. 393-412.
*. Wilmsmeier A, Ohrmann P, Suslow T, Siegmund A, Koelkebeck K, Rothermundt M, Kugel H,
Arolt V, Bauer J, Pedersen A. Neural correlates of set-shifting: decomposing executive functions
in schizophrenia. J Psychiatry Neurosci. 2010; 35(5):321–329. [PubMed: 20731964]
Windsor J, Kohnert K. The search for common ground: Part I. Lexical performance by linguistically
diverse learners. J Speech Lang Hear Res. 2004; 47(4):877–890. [PubMed: 15324292]
*. Wolf RC, Hose A, Frasch K, Walter H, Vasic N. Volumetric abnormalities associated with
cognitive deficits in patients with schizophrenia. Eur Psychiatry. 2008; 23(8):541–548. [PubMed:
18434103]
*. Xiang YT, Shum D, Chiu HF, Tang WK, Ungvari GS. Independent association of prospective
memory with retrospective memory and intelligence in schizophrenia: a controlled study. Arch
Clin Neuropsychol. 2010; 25(7):680–684. [PubMed: 20716544]

*. Zanelli J, Reichenberg A, Morgan K, Fearon P, Kravariti E, Dazzan P, Morgan C, Zanelli C,
Demjaha A, Jones PB, Doody GA, Kapur S, Murray RM. Specific and generalized
neuropsychological deficits: a comparison of patients with various first-episode psychosis
presentations. Am J Psychiatry. 2010; 167(1):78–85. [PubMed: 19952077]
*. Zanello A, Perrig L, Huguelet P. Cognitive functions related to interpersonal problem-solving skills
in schizophrenic patients compared with healthy subjects. Psychiatry Res. 2006; 142(1):67–78.
[PubMed: 16631929]
*. Zhou FC, Xiang YT, Wang CY, Dickerson F, Au RW, Zhou JJ, Zhou Y, Shum DH, Chiu HF, Man
D, Lee EH, Yu X, Chan RC, Ungvari GS. Characteristics and clinical correlates of prospective
memory performance in first-episode schizophrenia. Schizophr Res. 2012; 135(1–3):34–39.
[PubMed: 22222379]

Figure 1.
Selected effect sizes for impairment in schizophrenia relative to control performance.
Neuropsychological domain names are labeled in capital letters with black diamonds as
effect size markers. Selected individual variables in each domain are marked with small
black circles.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript
Table 1
Summary of meta-analytic results based on selected neuropsychological measures from 100 studies and 9048 people with schizophrenia.
Heterogeneity Test
Cognitive domain/measure Number of Studies Total Sample Size Effect Size Standard Error 95% Confidence Interval Z-value P-value Q Statistic P-value
Schaefer et al.
Grand mean 100 17146 −1.03 0.03 −1.09 to −0.96 30.26 <1 × 10−8 329.98 <1 × 10−8
Processing speed (ES = −1.25)
Digit symbol coding 22 7861 −1.55 0.11 −1.75 to −1.34 14.67 <1 × 10−8 271.79 <1 × 10−8
Trail Making Test part A 31 6388 −0.90 0.06 −1.02 to −0.78 15.05 <1 × 10−8 137.73 <1 × 10−8
Stroop color-reading condition 9 1117 −1.16 0.13 −1.42 to −0.90 8.75 <1 × 10−8 25.21 0.0014
IQ (ES = −1.13)
General IQ 31 6661 −1.11 0.08 − 1.26 to −0.96 14.54 <1 × 10−8 183.65 <1 × 10−8
Verbal IQ 8 2091 −1.09 0.20 −1.48 to −0.70 5.49 4.0 × 10−8 92.71 <1 × 10−8
Performance IQ 8 2096 −1.26 0.14 −1.54 to −0.99 8.87 <1 × 10−8 44.43 1.7 × 10−7
Verbal ability (ES = −0.68)
Word Reading 23 4579 −0.72 0.07 −0.86 to −0.58 10.30 <1 × 10−8 85.30 <1 × 10−8
Vocabulary 21 4008 −0.76 0.08 −0.90 to −0.61 10.01 <1 × 10−8 81.72 <1 × 10−8
Information 10 3524 −0.43 0.07 −0.56 to −0.29 6.02 <1 × 10−8 20.72 0.0140
Similarities 11 3811 −0.79 0.09 −0.97 to −0.62 8.80 <1 × 10−8 46.54 <1 × 10−8
Comprehension 6 684 −1.08 0.18 −1.43 to −0.74 6.11 <1 × 10−8 18.84 0.0021
Fluency (ES = −1.11)
Category fluency 41 6853 −1.21 0.07 −1.35 to −1.07 17.012 <1 × 10−8 229.66 <1 × 10−8
Letter fluency 36 4845 −0.98 0.06 −1.09 to −0.86 16.87 <1 × 10−8 95.25 1.7 × 10−7

Design fluency 4 464 −1.06 0.13 −1.31 to −0.80 8.12 <1 × 10−8 4.36 0.2252
Working memory (ES = −0.89)
Letter-number sequencing 25 4871 −1.02 0.05 −1.12 to −0.93 20.52 <1 × 10−8 47.69 0.0031
N back (2 back) 4 1939 −0.94 0.19 −1.32 to −0.56 4.87 1.1 × 10−6 30.58 1.0 × 10−6
Digit span forward 18 4589 −0.63 0.09 −0.81 to −0.45 6.77 <1 × 10−8 111.37 <1 × 10−8
Digit span backward 20 4466 −1.01 0.10 −1.21 to −0.81 9.84 <1 × 10−8 145.80 <1 × 10−8
Spatial span forward 7 705 −0.73 0.15 −1.03 to −0.44 4.87 1.1 × 10−6 20.53 0.0022
Spatial span backward 9 804 −0.91 0.10 −1.11 to −0.70 8.70 <1 × 10−8 14.31 0.0739
Page 18
Heterogeneity Test
Spatial span total 5 657 −0.81 0.22 −1.24 to −0.39 3.77 1.6 × 10−4 26.32 2.7 × 105
Motor speed (ES = −1.00)
Schaefer et al.
Grooved pegboard dominant 5 530 −0.86 0.17 −1.19 to −0.53 5.11 3.1 × 10−7 10.71 0.0300
Grooved pegboard nondominant 4 478 −0.94 0.22 −1.37 to −0.50 4.24 2.2 × 10−5 12.01 0.0073
Token Motor Task (BACS) 4 459 −1.23 0.17 −1.55 to −0.90 7.37 <1 × 10−8 6.89 0.0756
Episodic memory (ES = −1.23)
Word list learning 42 8906 −1.30 0.06 −1.42 to −1.19 21.83 <1 × 10−8 202.18 <1 × 10−8
Word list learning delayed 32 4601 −1.27 0.06 −1.38 to −1.15 21.24 <1 × 10−8 85.26 5.8 × 10−7
Word list recognition 10 2858 −0.68 0.06 −0.80 to −0.56 11.07 <1 × 10−8 13.25 0.1517
Story memory 16 5053 −1.41 0.09 −1.59 to −1.24 15.74 <1 × 10−8 92.90 <1 × 10−8
Story memory delayed 14 4681 −1.40 0.11 −1.60 to −1.19 13.09 <1 × 10−8 104.16 <1 × 10−8
Figure learning 14 4345 −1.10 0.14 −1.37 to −0.84 8.18 <1 × 10−8 171.98 <1 × 10−8
Figure learning delayed 16 4528 −1.21 0.14 −1.48 to −0.94 8.78 <1 × 10−8 209.49 <1 × 10−8
Visuospatial/problem solving (ES = −0.73)
Block design 11 4930 −0.71 0.09 −0.89 to −0.52 7.60 <1 × 10−8 69.21 <1 × 10−8
Matrix Reasoning 12 1813 −0.90 0.07 −1.03 to −0.78 14.00 <1 × 10−8 14.65 0.1989
Figure copy 7 943 −0.64 0.17 −0.97 to −0.31 3.84 1.2 × 10−4 31.49 2.0 × 10−5
Picture completion 5 505 −0.64 0.12 −0.87 to −0.41 5.41 6× 10−8 6.14 0.1891
Executive functioning (ES = −0.94)
Trail Making Test part B 37 7267 −1.08 0.06 −1.18 to −0.97 19.72 <1 × 10−8 128.24 <1 × 10−8
Stroop color-word condition 11 2764 −1.11 0.13 −1.36 to −0.85 8.55 <1 × 10−8 76.24 <1 × 10−8

Stroop interference 11 1222 −0.62 0.11 −0.83 to −0.41 5.80 <1 × 10−8 25.56 0.0044
WCST categories 33 6264 −0.87 0.07 −1.00 to −0.74 12.97 <1 × 10−8 157.86 <1 × 10−8
WCST perseverative errors 31 5232 −0.90 0.08 −1.05 to −0.75 11.78 <1 × 10−8 163.09 <1 × 10−8
WCST % perseverative errors 5 547 −0.68 0.10 −0.86 to −0.49 7.18 <1 × 10−8 3.31 <1 × 10−8
WCST total errors 7 695 −0.85 0.08 −1.01 to −0.69 10.58 <1 × 10−8 1.01 0.9854
Zoo Map 4 415 −1.09 0.11 −1.31 to −0.88 10.08 <1 × 10−8 2.33 0.5072
Tower Tasks total correct score 9 1358 −0.88 0.13 −1.13 to −0.64 6.97 <1 × 10−8 31.71 1.0 × 10−4
Sustained attention (ES = −1.07)
Page 19
Heterogeneity Test
Identical pairs CPT (d′) 9 1257 −1.10 0.09 −1.28 to −0.91 11.72 <1 × 10−8 15.67 0.0474
Degraded stimulus CPT (rt) 5 750 −1.04 0.15 −1.33 to −0.75 6.97 <1 × 10−8 10.88 0.0279
Schaefer et al.

Page 20
Table 2
Side by side comparison of results from three meta-analysis samples comparing schizophrenia cognitive performance to controls, covering the years 1980
to 2012.
Heinrichs & Zakzanis (1998); Zakzanis et al. (1999) Dickinson et al. (2007) Current analysis
Schaefer et al.
Time period covered 1980–1997 1995–2006 2006–2012

Schizophrenia % male 82.4 … 66.8
Overall number of studies included 204 37 100
Mean SD Mean SD Mean SD

Schizophrenia sample age 34.4 10.0 31.5 7.3 35.1 9.5
Schizophrenia sample education 12.0 1.1 12.3 1.1 12.1 2.6
Duration of illness 12.7 7.6 9.1 5.9 13.2 9.3
Sample size per study 36.1 30.2 53 33.9 90.5 128.4
Effect Size Schizophrenia Sample Size Effect Size Schizophrenia Sample Size Effect Size Schizophrenia Sample Size
Meta-analysis Grand Mean 0.92 7420 0.98 1961 1.02 8617
Full Scale or Estimated IQ 1.1 1018 1.19 863 1.11 3273
Word Reading (“Premorbid IQ”) 0.42 1069 0.59 450 0.72 2087
WAIS Vocabulary 0.53 2046 0.9 586 0.76 1791

WAIS Block Design 0.46 1166 0.84 607 0.71 2179
Combined Verbal Learning 1.41 1088 … … … …

Story Learning … … 1.19 863 1.41 2358
List Learning … … 1.25 1254 1.30 4730

Nonverbal/Figure Learning 0.74 379 0.82 544 1.10 1949
WCST Categories 1.01 1387 0.81 1018 0.87 2999

WCST Perseverative Errors 1.06 1387 0.79 1295 0.90 2393
Coding/Digit Symbol 1.11 1204 1.57 1961 1.55 3680

Trail Making Test, Form A 0.7 1204 0.88 1081 0.90 3114
Trail Making Test, Form B 0.8 1387 0.92 1190 1.08 3362
Page 21
Heinrichs & Zakzanis (1998); Zakzanis et al. (1999) Dickinson et al. (2007) Current analysis
WAIS Digit Span Forward 0.69 440 0.73 175 0.63 1970
WAIS Digit Span Backward 0.82 440 0.86 155 1.01 2026
Combined Verbal Fluency 1.15 1020 … … … …

Schaefer et al.
Letter Fluency … … 0.83 1213 0.98 2300

Category Fluency … … 1.41 462 1.21 3166

Page 22
Table 3
Results of a test-by-test comparative analysis investigating the extent to which effect sizes obtained from the main meta-analysis are robust to differences
in geographic location. Measures used in fewer than 3 studies from a given region were excluded from this analysis.
Cognitive domain/measure North America Europe Asia Qbetween P-value

Schaefer et al.
Grand mean No. of studies 28 47 17 0.210 0.976

N Schizophrenics 2114 4435 1498
Effect Size 1.04 1.02 1.08
Processing speed
Digit symbol coding N Schizophrenics 772 2250 548 0.150 0.928
Effect Size 1.45 1.58 1.56
Qwithin 86.86** 69.50** 104.63**
Trail Making Test part A N Schizophrenics 963 1576 365 2.043 0.564
Effect Size 1.04 0.89 0.87
Qwithin 25.28* 38.99* 30.76**
Intellectual/verbal ability
General IQ N Schizophrenics 275 2446 552 1.844 0.605
Effect Size 1.26 1.09 1.01
Qwithin 8.24 115.95** 55.15**
Word Reading N Schizophrenics 1247 309 330 3.172 0.205
Effect Size 0.78 0.51 1.05
Qwithin 32.85** 20.03* 22.42**

Vocabulary N Schizophrenics 347 1090 354 8.936 0.011
Effect Size 0.99 0.56 0.95
Qwithin 21.32* 30.01** 7.19*
Fluency
Category fluency N Schizophrenics 712 1482 673 1.802 0.615
Effect Size 1.02 1.29 1.22
Qwithin 43.25** 62.17** 79.75**
Letter fluency N Schizophrenics 691 1120 285 6.546 0.088
Page 23
Effect Size 0.90 1.14 0.87

Qwithin 4.45 67.45** 1.33
Episodic memory
Schaefer et al.
Word list learning N Schizophrenics 1394 2626 407 1.272 0.736

Effect Size 1.34 1.27 1.49
Qwithin 48.70** 73.82** 15.84**
Word list learning delayed N Schizophrenics 577 1260 355 3.711 0.294
Effect Size 1.32 1.22 1.40
Qwithin 6.75 59.76** 2.06
Story memory N Schizophrenics 746 786 749 0.948 0.814

Effect Size 1.52 1.34 1.43
Qwithin 8.55* 30.50** 45.65**
Story memory delayed N Schizophrenics 667 785 626 1.874 0.599
Effect Size 1.09 1.43 1.60
Qwithin 35.52** 18.47* 40.82**
Perceptual/problem solving
Block design N Schizophrenics 166 1445 568 4.119 0.128
Effect Size 0.83 0.53 0.85
Qwithin 0.94 20.62** 20.69**
Executive functioning

Trail Making Test part B N Schizophrenics 1186 1529 523 21.541 8.13 × 10−5
Effect Size 1.26 1.05 0.85
Qwithin 9.73 35.19* 18.82**
Stroop color-word condition N Schizophrenics 330 433 328 3.219 0.200
Effect Size 1.17 1.28 0.77
Qwithin 4.35 7.19 14.97**
WCST categories N Schizophrenics 1086 1009 709 0.455 0.929
Effect Size −0.86 −0.86 −0.82
Page 24
Qwithin 77.21** 35.08** 13.56
WCST perseverative errors N Schizophrenics 827 811 701 2.690 0.442

Effect Size −0.80 −0.82 −1.07
Schaefer et al.
Qwithin 15.68* 18.12 116.75**
*
p < .05,
**
p ≤ 0.01

Page 25

Ni Hms 509207

Uploaded by

Copyright:

Available Formats

Ni Hms 509207

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ni Hms 509207

Uploaded by

Copyright:

Available Formats

NIH Public Access

Schizophr Res. 2013 October ; 150(1): 42–50. doi:10.1016/j.schres.2013.07.009.

The global cognitive impairment in schizophrenia: Consistent

Objective—Schizophrenia results in cognitive impairments as well as positive, negative, and

Conclusions—The present study extends findings from 1980–2006 of a substantial, generalized

educational achievement, and a marked decrease in life expectancy.

UCSD Performance-based Skills Assessment, suggesting a high degree of criterion validity

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

A question in the field is whether decreased PubMed references to a “generalized deficit” in

2. Materials and methods

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

these articles, yielding 376 studies in total.

Finally, we recorded information about a number of potential moderator variables. The

functioning. We also examined demographic variables including participants’ sex, level of

2.2. Data analysis

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

test of differences in degree of impairment across domains (e.g., group-by-domain

3.2 Moderator variable analyses

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Interestingly, our moderator analyses found no significant relationship between duration of

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Assessment of Functioning (GAF; Karilampi et al., 2011), we found no significant

In summary, this analysis of studies using contemporary neuropsychological tests and

Role of Funding Source

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

*. Ammari N, Heinrichs RW, Miles AA. An investigation of 3 neurocognitive subtypes in

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Garyfallos G. Sex differences in neuropsychological functioning among schizophrenia patients.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

J, Nicolini H, Raventos H, Escamilla MA. Adjudicating neurocognitive endophenotypes for

Schizophrenia. Oxford University Press; Oxford, England: 2000. p. 178-192.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

variant in the ZNF804A gene on memory function in schizophrenia. Am J Med Genet B

Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol. 2005; 60(3):229–242.

*. Hu M, Chen J, Li L, Zheng Y, Wang J, Guo X, Wu R, Zhao J. Semantic fluency and executive

Rehabil. 2007; 17(2):192–205. [PubMed: 17454693]

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

254–261. [PubMed: 16914246]

*. Manning V, Betteridge S, Wanigaratne S, Best D, Strang J, Gossop M. Cognitive impairment in

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

*. Ngoma M, Vansteelandt K, Delespaul P, Krabbendam L, Miezi SM, Peuskens J. Cognitive deficits

Grade. Top Lang Disord. 2006; 26(4):338–350. [PubMed: 20396623]

McGlashan T. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms,

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

*. Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F,

controls. Eur Psychiatry. 2011; 26(2):69–73. [PubMed: 20435446]

*. Tabares-Seisdedos R, Balanza-Martinez V, Sanchez-Moreno J, Martinez-Aran A, Salazar-Fraile J,

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

*. Wang X, Yao S, Kirkpatrick B, Shi C, Yi J. Psychopathology and neuropsychological impairments

Clin Neuropsychol. 2010; 25(7):680–684. [PubMed: 20716544]

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Schizophr Res. Author manuscript; available in PMC 2014 October 14.

Time period covered 1980–1997 1995–2006 2006–2012

Mean SD Mean SD Mean SD

WAIS Vocabulary 0.53 2046 0.9 586 0.76 1791

Qwithin 77.21 35.08 13.56